Drug intelligence / Profile preview

PYR-001

Development stage: Preclinical
Lead developer: Pyros Pharmaceuticals

Overview

PYR-001 is an early-stage pipeline candidate developed by Pyros Pharmaceuticals, a specialty pharmaceutical company focused on rare pediatric diseases, particularly infantile spasms and rare forms of epilepsy. Pyros was acquired by Bora Pharmaceuticals in 2024 and is integrated with Upsher-Smith. As of 2024, PYR-001 is in the preclinical or early development phase. Publicly available information regarding its specific active ingredient, molecular target, and modality is currently limited, as the company has not yet disclosed these details.

Beyond the preview

Go deeper on PYR-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PYR-001.

Explore the full profile